NCT00911612View on ClinicalTrials.gov

Does Welchol (Colesevelam Hydrochloride) Improve Colonic Transit in Diarrhea-predominant Irritable Bowel Syndrome (D-IBS)?

PHASE2CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

January 31, 2009

Primary Completion Date

May 31, 2009

Study Completion Date

May 31, 2009

Conditions
Irritable Bowel SyndromeDiarrhea
Interventions
DRUG

Colesevelam

Welchol (Colesevelam HCL) 1.875 gram twice daily for 12-14 days

DRUG

Placebo

Inert capsule matching the study drug, given twice daily

Trial Locations (1)

55905

Mayo Clinic, Rochester

Sponsors

Lead Sponsor

Mayo Clinic
All Listed Sponsors
collaborator

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

NIH

lead

Mayo Clinic

OTHER

NCT00911612 - Does Welchol (Colesevelam Hydrochloride) Improve Colonic Transit in Diarrhea-predominant Irritable Bowel Syndrome (D-IBS)? | Biotech Hunter | Biotech Hunter